ARNA Quote, Trading Chart, Arena Pharmaceuticals Inc.
home / stock / arna / arna quote
$65.19 Last:
0.82% Change Percent:
$64.71 Open:
$65.19 Previous Close:
$65.68 High:
$63.59 Low:
405,555 Volume:
06/11/2021 04:42:19 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ARNA Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-11 | 64.71 | 65.19 | 65.68 | 63.59 | 405,555 |
| 2021-06-10 | 62.17 | 64.66 | 65.45 | 61.65 | 447,065 |
| 2021-06-09 | 61.11 | 62.28 | 62.37 | 60.715 | 445,477 |
| 2021-06-08 | 61.34 | 60.86 | 62.4 | 59.9 | 339,744 |
| 2021-06-07 | 60.51 | 61.05 | 62.72 | 60.26 | 653,040 |
| 2021-06-04 | 61.28 | 60.6 | 61.6553 | 60.485 | 293,005 |
| 2021-06-03 | 60.99 | 61.28 | 61.83 | 60.59 | 292,386 |
| 2021-06-02 | 62.55 | 61.69 | 63.065 | 60.69 | 557,718 |
| 2021-06-01 | 61.6 | 62.58 | 63.47 | 61.14 | 460,849 |
| 2021-05-31 | 62.01 | 61.11 | 62.97 | 60.79 | 544,240 |
| 2021-05-28 | 62.01 | 61.11 | 62.97 | 60.79 | 543,667 |
| 2021-05-27 | 62.06 | 61.92 | 62.68 | 61.2189 | 218,943 |
| 2021-05-26 | 62.65 | 61.75 | 62.7 | 61.1 | 214,715 |
| 2021-05-25 | 62.81 | 62.14 | 63.64 | 62.12 | 326,676 |
| 2021-05-24 | 63.12 | 62.81 | 63.37 | 62.235 | 291,050 |
| 2021-05-21 | 62.96 | 62.79 | 63.9 | 62.445 | 378,439 |
| 2021-05-20 | 61.07 | 62.96 | 63 | 60.44 | 376,420 |
| 2021-05-19 | 60.36 | 61.13 | 61.57 | 60.01 | 361,079 |
| 2021-05-18 | 61.8 | 61.57 | 63.15 | 61.3 | 431,244 |
| 2021-05-17 | 61.49 | 60.89 | 61.9 | 60.09 | 300,550 |
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
– EoE affects approximately 135,000 in the US and an estimated 132,000 patients in the EU4 and United Kingdom – Currently no FDA approved therapies in the US for the treatment of EoE Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that th...
-
– Evaluating the safety, tolerability, and efficacy of intravenous (IV) temanogrel for cMVO in adult participants undergoing percutaneous coronary intervention (PCI) – Currently no FDA approved therapies indicated for the treatment of cMVO – Temano...
-
- Improvement by two score levels to "A" following the Company’s 2021 ESG Report launch underscores Arena's long-term commitment to ESG principles Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of "A."...